DB:2I3

Stock Analysis Report

Executive Summary

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.

Snowflake

Fundamentals

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Champions Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.8%

2I3

1.4%

DE Life Sciences

3.9%

DE Market


1 Year Return

-49.0%

2I3

7.2%

DE Life Sciences

3.4%

DE Market

Return vs Industry: 2I3 underperformed the German Life Sciences industry which returned 7.2% over the past year.

Return vs Market: 2I3 underperformed the German Market which returned 3.4% over the past year.


Shareholder returns

2I3IndustryMarket
7 Day3.8%1.4%3.9%
30 Day6.9%-2.1%2.1%
90 Day-20.0%-4.4%3.7%
1 Year-49.0%-49.0%8.1%7.2%6.7%3.4%
3 Yearn/a64.1%55.9%18.9%8.6%
5 Yearn/a227.4%202.1%41.8%22.5%

Price Volatility Vs. Market

How volatile is Champions Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Champions Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: 2I3 (€5.4) is trading below our estimate of fair value (€10.84)

Significantly Undervalued: 2I3 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2I3 is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: 2I3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 2I3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2I3 is overvalued based on its PB Ratio (42x) compared to the XE Life Sciences industry average (3.5x).


Next Steps

Future Growth

How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

106.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2I3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2I3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2I3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2I3's revenue (19% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 2I3's revenue (19% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: 2I3's Return on Equity is forecast to be very high in 3 years time (42.2%).


Next Steps

Past Performance

How has Champions Oncology performed over the past 5 years?

42.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 2I3 is unprofitable, but has reduced losses over the past 5 years at a rate of 42.4% per year.

Accelerating Growth: Unable to compare 2I3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2I3 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14%).


Return on Equity

High ROE: 2I3 has a negative Return on Equity (-57.58%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 2I3 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 2I3 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Champions Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: 2I3's short term assets ($6.3M) do not cover its short term liabilities ($7.9M)

Long Term Liabilities: 2I3's short term assets (6.3M) exceeds its long term liabilities (3.7M)


Debt to Equity History and Analysis

Debt Level: 2I3 is debt free.

Reducing Debt: 2I3 had no debt 5 years ago.


Balance Sheet

Inventory Level: 2I3 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2I3's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2I3 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2I3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Champions Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 2I3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2I3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 2I3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2I3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2I3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Champions Oncology's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Ronnie Morris (53yo)

2.8yrs

Tenure

US$146,281

Compensation

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris served as the President at Champions oncology, Inc., since October 26, 2010 until Jan ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ronnie's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 2I3's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

6.6yrs

Average Tenure

54yo

Average Age

Experienced Board: 2I3's board of directors are considered experienced (6.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$130,23020 Dec 18
Ronnie Morris
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares20,000
Max PriceUS$6.51
SellUS$60,23908 Nov 18
Daniel Mendelson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$12.05

Ownership Breakdown


Management Team

  • Philip Breitfeld (66yo)

    Chief Strategy & Innovation Officer and Director

    • Tenure: 3.5yrs
    • Compensation: US$33.30k
  • Ronnie Morris (53yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$146.28k
  • David Miller (50yo)

    Chief Financial Officer

    • Tenure: 6.3yrs
    • Compensation: US$250.00k
  • Mark Weinstein

    Chief Information Officer

    • Tenure: 4.2yrs
  • Bruce Ruggeri

    Chief Scientific Officer

    • Tenure: 0.8yrs

Board Members

  • Scott Tobin (48yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$39.96k
  • Joel Ackerman (54yo)

    Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: US$66.60k
  • David Sidransky (59yo)

    Lead Director

    • Tenure: 2.9yrs
    • Compensation: US$33.30k
  • Manuel Hidalgo (51yo)

    Scientific Advisor

    • Tenure: 0yrs
  • Dan Mendelson (54yo)

    Independent Director

    • Tenure: 6.6yrs
    • Compensation: US$39.96k
  • Harvey Pass

    Scientific Advisor

    • Tenure: 0yrs
  • Abba Poliakoff (67yo)

    Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$39.96k
  • Philip Breitfeld (66yo)

    Chief Strategy & Innovation Officer and Director

    • Tenure: 3.5yrs
    • Compensation: US$33.30k
  • Misti Ushio (48yo)

    Board Observer

    • Tenure: 0yrs
  • Ronnie Morris (53yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$146.28k

Company Information

Champions Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Champions Oncology, Inc.
  • Ticker: 2I3
  • Exchange: DB
  • Founded: 1985
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$70.298m
  • Listing Market Cap: US$63.205m
  • Shares outstanding: 11.62m
  • Website: https://www.championsoncology.com

Number of Employees


Location

  • Champions Oncology, Inc.
  • One University Plaza
  • Suite 307
  • Hackensack
  • New Jersey
  • 7601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSBRNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 1988
2I3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1988

Biography

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approac ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 22:09
End of Day Share Price2019/10/17 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.